Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study - Rini, BI; Pal, SK; Escudier, BJ (Lancet Oncol, 2020)
et al.